Trevi Therapeutics Inc

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops and commercializes investigational therapies for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. Its lead product, Haduvio, is an oral extended-release formulation of nalbuphine. Haduvio is being evaluated in a Phase 2b trial for cough reduction in IPF and a Phase 2a trial in refractory chronic cough. The company has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics was incorporated in 2011 and is headquartered in New Haven, Connecticut.

TRVI▲

Trevi Therapeutics initiates Phase 3 OCEAN-1 trial for IPF-related chronic cough

Trevi Therapeutics initiated its Phase 3 OCEAN-1 trial for patients with idiopathic pulmonary fibrosis-related chronic cough in the second quarter of 2026. The company also started the Phase 2b LAKE trial for refractory chronic cough and expects to begin the Phase 3 OCEAN-2 trial in the third quarter. Trevi ended the quarter with $318.9 million in cash, cash equivalents and marketable securities, bolstered by a $162.3 million stock offering in April, and reported a net loss of $17.8 million. The company plans to meet with the FDA regarding a development plan for non-IPF ILD-related chronic cough and expects topline data from OCEAN-1 in the first half of 2028.

TRVI ▲

GlobeNewswire·43dRead more →